Trials / Conditions / Purpura, Thrombocytopenic, Idiopathic

Purpura, Thrombocytopenic, Idiopathic

30 registered clinical trials studyying Purpura, Thrombocytopenic, Idiopathic.

Status	Trial	Sponsor	Phase
Withdrawn	The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune NCT06291415	Hutchmed	Phase 1
Completed	The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9 NCT05438875	Peking University People's Hospital	Phase 3
Unknown	Optimization of Glucocorticoid Taper Strategies for SLE-ITP NCT05506033	Fujian Medical University Union Hospital	N/A
Unknown	Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP NCT03252457	Shandong University	Phase 3
Unknown	Rituximab Combining Bortezomib Versus Rituximab in Management of ITP NCT03443570	Shandong University	Phase 3
Completed	A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Par NCT03275454	Bioverativ, a Sanofi company	Phase 1
Unknown	The PROLONG Trial - Rituximab Maintenance Therapy in ITP NCT03010202	Ostfold Hospital Trust	Phase 3
Completed	Regulatory B Cells and Chronic Immune Thrombocytopenia NCT02891109	University Hospital, Brest	—
Completed	Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects NCT02281370	GlaxoSmithKline	Phase 1
Unknown	A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients NCT02403440	Jiangsu HengRui Medicine Co., Ltd.	Phase 1
Terminated	Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary NCT02009761	Boehringer Ingelheim	Phase 1
Completed	A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopeni NCT02201290	Novartis Pharmaceuticals	Phase 3
Completed	Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disord NCT01610180	Fondazione Progetto Ematologia	Phase 2
Withdrawn	Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia NCT01317966	Ming Hou	—
Completed	Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects NCT01327872	Eisai Inc.	Phase 1
Completed	High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocyt NCT01356511	Shandong University	Phase 4
Unknown	The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia. NCT01101295	Henri Mondor University Hospital	—
Completed	The Study of Different Dose Rituximab in the Treatment of ITP NCT03258866	Shandong University	Phase 4
Completed	Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) NCT00828750	GlaxoSmithKline	Phase 3
Terminated	Study of Veltuzumab (hA20) at Different Doses in Patients With ITP NCT00547066	Gilead Sciences	Phase 1 / Phase 2
Completed	Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) NCT00540423	GlaxoSmithKline	Phase 3
Completed	Eltrombopag Taste Testing in Healthy Adult Volunteers NCT00487968	GlaxoSmithKline	Phase 1
Completed	Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytope NCT00441090	Eisai Inc.	Phase 2
Completed	Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Pur NCT00706342	Rigel Pharmaceuticals	Phase 2
Completed	Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) NCT00372892	Hamilton Health Sciences Corporation	Phase 2
Completed	Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP NCT00220727	Grifols Therapeutics LLC	Phase 2
Completed	Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia NCT02334813	University Hospital, Essen	Phase 3
Completed	Efficacy and Safety of IVIG-L in ITP Patients NCT00151840	Prothya Biosolutions	Phase 3
Completed	Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura NCT00005652	University of Alabama at Birmingham	Phase 2
Completed	An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between NCT00005570	National Heart, Lung, and Blood Institute (NHLBI)	—